\BOOKMARK [0][-]{chapter.4}{Synthetic Lethal Analysis of Gene Expression Data}{}% 118
\BOOKMARK [1][-]{section.4.1}{Synthetic lethal genes in breast cancer}{chapter.4}% 119
\BOOKMARK [2][-]{subsection.4.1.1}{Synthetic lethal pathways in breast cancer}{section.4.1}% 120
\BOOKMARK [2][-]{subsection.4.1.2}{Expression profiles of synthetic lethal partners}{section.4.1}% 121
\BOOKMARK [3][-]{subsubsection.4.1.2.1}{Subgroup pathway analysis}{subsection.4.1.2}% 122
\BOOKMARK [1][-]{section.4.2}{Comparison of synthetic lethal gene candidates}{chapter.4}% 123
\BOOKMARK [2][-]{subsection.4.2.1}{Comparison with siRNA screen candidates}{section.4.2}% 124
\BOOKMARK [3][-]{subsubsection.4.2.1.1}{Comparison with correlation}{subsection.4.2.1}% 125
\BOOKMARK [3][-]{subsubsection.4.2.1.2}{Comparison with viability}{subsection.4.2.1}% 126
\BOOKMARK [3][-]{subsubsection.4.2.1.3}{Comparison with secondary screen siRNA screen candidates}{subsection.4.2.1}% 127
\BOOKMARK [3][-]{subsubsection.4.2.1.4}{Comparison of screen at pathway level}{subsection.4.2.1}% 128
\BOOKMARK [4][-]{subsubsubsection.4.2.1.4.1}{Resampling of genes for pathway enrichment}{subsubsection.4.2.1.4}% 129
\BOOKMARK [1][-]{section.4.3}{Metagene Analysis}{chapter.4}% 130
\BOOKMARK [2][-]{subsection.4.3.1}{Pathway expression}{section.4.3}% 131
\BOOKMARK [2][-]{subsection.4.3.2}{Somatic mutation}{section.4.3}% 132
\BOOKMARK [2][-]{subsection.4.3.3}{Mutation locus}{section.4.3}% 133
\BOOKMARK [2][-]{subsection.4.3.4}{Synthetic lethal metagenes}{section.4.3}% 134
\BOOKMARK [1][-]{section.4.4}{Replication in stomach cancer}{chapter.4}% 135
\BOOKMARK [2][-]{subsection.4.4.1}{Synthetic Lethal Genes and Pathways}{section.4.4}% 136
\BOOKMARK [2][-]{subsection.4.4.2}{Synthetic Lethal Expression Profiles}{section.4.4}% 137
\BOOKMARK [2][-]{subsection.4.4.3}{Comparison to Primary Screen}{section.4.4}% 138
\BOOKMARK [3][-]{subsubsection.4.4.3.1}{Resampling Analysis}{subsection.4.4.3}% 139
\BOOKMARK [2][-]{subsection.4.4.4}{Metagene Analysis}{section.4.4}% 140
\BOOKMARK [1][-]{section.4.5}{Global Synthetic Lethality}{chapter.4}% 141
\BOOKMARK [2][-]{subsection.4.5.1}{Hub Genes}{section.4.5}% 142
\BOOKMARK [2][-]{subsection.4.5.2}{Hub Pathways}{section.4.5}% 143
\BOOKMARK [1][-]{section.4.6}{Replication in cell line encyclopaedia}{chapter.4}% 144
\BOOKMARK [1][-]{section.4.7}{Discussion}{chapter.4}% 145
\BOOKMARK [2][-]{subsection.4.7.1}{Strengths of the SLIPT Methodology}{section.4.7}% 146
\BOOKMARK [2][-]{subsection.4.7.2}{Syntheic Lethal Pathways for E-cadherin}{section.4.7}% 147
\BOOKMARK [2][-]{subsection.4.7.3}{Replication and Validation}{section.4.7}% 148
\BOOKMARK [3][-]{subsubsection.4.7.3.1}{Integration with siRNA Screening}{subsection.4.7.3}% 149
\BOOKMARK [3][-]{subsubsection.4.7.3.2}{Replication across Tissues and Cell lines}{subsection.4.7.3}% 150
\BOOKMARK [1][-]{section.4.8}{Summary}{chapter.4}% 151
\BOOKMARK [0][-]{section*.38}{References}{}% 178
